LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that ABRAXANE® powder for suspension for infusion (an albumin-bound nanoparticle formulation of paclitaxel), has received a positive opinion in favor of approval from the European Committee for Human Medicinal Products (CHMP) for the treatment of metastatic breast cancer in women who have failed therapy in the first-line setting. The CHMP positive opinion was based on the clinical trial data that supported the approval of ABRAXANE in the United States and Canada. In that trial, ABRAXANE demonstrated significant superiority in the clinical endpoints of response rate, progression free survival and survival when compared with Taxol® in the proposed indication in metastatic breast cancer.
